Hansson, Oskar

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers

Mattsson-Carlgren, N., Salvadó, G., Ashton, N. J., Tideman, P., Stomrud, E., Zetterberg, H., Ossenkoppele, R., Betthauser, T. J., Cody, K. A., Jonaitis, E. M., et al. (2023) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 309

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease

Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., et al. (2014) · Molecular Neurodegeneration

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 293

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

Jansen, W. J., Janssen, O., Tijms, B. M., Vos, S. J. B., Ossenkoppele, R., Visser, P. J., Amyloid Biomarker Study Group, Aarsland, D., Alcolea, D., Altomare, D., et al. (2022) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 290

CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease

Westin, K., Buchhave, P., Nielsen, H., Minthon, L., Janciauskiene, S., & Hansson, O. (2012) · PLoS ONE

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 277

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease

Whelan, C. D., Mattsson, N., Nagle, M. W., Vijayaraghavan, S., Hyde, C., Janelidze, S., Stomrud, E., Lee, J., Fitz, L., Samad, T. A., et al. (2019) · Acta Neuropathologica Communications

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 262

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau

Mattsson‐Carlgren, N., Janelidze, S., Bateman, R. J., Smith, R., Stomrud, E., Serrano, G. E., Reiman, E. M., Palmqvist, S., Dage, J. L., Beach, T. G., et al. (2021) · EMBO Molecular Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 261

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease

Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., et al. (2023) · Nature Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 249

A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases

Brum, W. S., Cullen, N. C., Janelidze, S., Ashton, N. J., Zimmer, E. R., Therriault, J., Benedet, A. L., Rahmouni, N., Tissot, C., Stevenson, J., et al. (2023) · Nature Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 248

Early stages of tau pathology and its associations with functional connectivity, atrophy and memory

Berron, D., Vogel, J. W., Insel, P. S., Pereira, J. B., Xie, L., Wisse, L. E. M., Yushkevich, P. A., Palmqvist, S., Mattsson-Carlgren, N., Stomrud, E., et al. (2021) · Brain

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 240

Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype

Janelidze, S., Hertze, J., Nägga, K., Nilsson, K., Nilsson, C., Wennström, M., van Westen, D., Blennow, K., Zetterberg, H., & Hansson, O. (2017) · Neurobiology of Aging

Barrier Structure and Function StudiesCerebrospinal fluid and hydrocephalus

Cited by 237

Staging β -Amyloid Pathology With Amyloid Positron Emission Tomography

Mattsson, N., Palmqvist, S., Stomrud, E., Vogel, J., & Hansson, O. (2019) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 237

Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum

Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O. (2012) · PLoS ONE

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 236

Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity

Hansson, O., Petersén, Å., Leist, M., Nicotera, P., Castilho, R. F., & Brundin, P. (1999) · Proceedings of the National Academy of Sciences

Genetic Neurodegenerative DiseasesNeuroscience and Neuropharmacology Research

Cited by 228

Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance

Pichet Binette, A., Janelidze, S., Cullen, N., Dage, J. L., Bateman, R. J., Zetterberg, H., Blennow, K., Stomrud, E., Mattsson‐Carlgren, N., & Hansson, O. (2023) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 226

Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease

Zetterberg, H., Andreasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M. E., Buchhave, P., Londos, E., Umek, R. M., Minthon, L., et al. (2008) · Archives of Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 224

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders

Leuzy, A., Smith, R., Ossenkoppele, R., Santillo, A., Borroni, E., Klein, G., Ohlsson, T., Jögi, J., Palmqvist, S., Mattsson-Carlgren, N., et al. (2020) · JAMA Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 222

Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

Salvadó, G., Ossenkoppele, R., Ashton, N. J., Beach, T. G., Serrano, G. E., Reiman, E. M., Zetterberg, H., Mattsson‐Carlgren, N., Janelidze, S., Blennow, K., et al. (2023) · EMBO Molecular Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 205

Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease

Thorsell, A., Bjerke, M., Gobom, J., Brunhage, E., Vanmechelen, E., Andreasen, N., Hansson, O., Minthon, L., Zetterberg, H., & Blennow, K. (2010) · Brain Research

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 204

Prevalence of amyloid‐β pathology in distinct variants of primary progressive aphasia

Bergeron, D., Gorno‐Tempini, M. L., Rabinovici, G. D., Santos‐Santos, M. A., Seeley, W., Miller, B. L., Pijnenburg, Y., Keulen, M. A., Groot, C., van Berckel, B. N. M., et al. (2018) · Annals of Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 203

Mitochondrial Control of Acute Glutamate Excitotoxicity in Cultured Cerebellar Granule Cells

Castilho, R. F., Hansson, O., Ward, M. W., Budd, S. L., & Nicholls, D. G. (1998) · The Journal of Neuroscience

Mitochondrial Function and PathologyNeuroscience and Neuropharmacology Research

Cited by 197

Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau

Janelidze, S., Palmqvist, S., Leuzy, A., Stomrud, E., Verberk, I. M. W., Zetterberg, H., Ashton, N. J., Pesini, P., Sarasa, L., Allué, J. A., et al. (2022) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 188

Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations

Cullen, N. C., Leuzy, A., Palmqvist, S., Janelidze, S., Stomrud, E., Pesini, P., Sarasa, L., Allué, J. A., Proctor, N. K., Zetterberg, H., et al. (2020) · Nature Aging

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 187

Amyloid blood biomarker detects Alzheimer's disease

Nabers, A., Perna, L., Lange, J., Mons, U., Schartner, J., Güldenhaupt, J., Saum, K., Janelidze, S., Holleczek, B., Rujescu, D., et al. (2018) · EMBO Molecular Medicine

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 185

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease

Öhrfelt, A., Brinkmalm, A., Dumurgier, J., Brinkmalm, G., Hansson, O., Zetterberg, H., Bouaziz-Amar, E., Hugon, J., Paquet, C., & Blennow, K. (2016) · Alzheimer's Research & Therapy

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 184